Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 4/20 | 0.43 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20420131 | 0.79 | YTHDC1 (0.49) | YTHDC1YTHDF2PDPK1CSF1RADORA3 | |
| SCHEMBL16682266 | 0.77 | — | — | |
| SCHEMBL355788 | 0.76 | GSK3B (0.41) | YTHDC1YTHDF2PDPK1CSF1RADORA1 | |
| SCHEMBL29923950 | 0.76 | GSK3B (0.41) | YTHDC1YTHDF2PDPK1CSF1RADORA1 | |
| SCHEMBL10960612 | 0.76 | — | — | |
| SCHEMBL10442146 | 0.75 | NUDT1 (0.46) | YTHDC1YTHDF2PDPK1CSF1RMAP4K4 | |
| SCHEMBL42336 | 0.75 | PIK3CG (0.42) | ADORA1ADORA2A | |
| SCHEMBL8823861 | 0.75 | — | — | |
| SCHEMBL21913 | 0.67 | YTHDC1 (0.47) | YTHDC1YTHDF2PDPK1CSF1RADORA3 | |
| SCHEMBL6272986 | 0.65 | YTHDC1 (0.46) | YTHDC1YTHDF2PDPK1CSF1RADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150211004-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-30 | — | — | US | claimed |
| EP-2838541-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | Agency For Science, Technology And Research (SG) | 2015-02-25 | — | — | EP | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | claimed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | claimed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | claimed |
| US-12638452-B2 | Nanopore assemblies and uses thereof | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-26 | — | — | US | disclosed |
| CN-122029282-A | Novel aptamers to EphA2 (hepaplatin receptor 2 a) | 阿普塔德尔治疗公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CARIS SCIENCE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | UNIV ARIZONA STATE (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONE STATE UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260041702-A1 | AGENTS THAT INHIBIT CCN LIGAND-INDUCED SIGNALLING FOR TREATING DISEASE | TRIBUNE THERAPEUTICS AB (SE) | 2026-02-12 | — | — | US | disclosed |
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| EP-0549686-A1 | MODIFIED INTERNUCLEOSIDE LINKAGES | GILEAD SCIENCES, INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| WO-1993009127-A1 | ENHANCED TRIPLE-HELIX FORMATION DIRECTED BY OLIGONUCLEOTIDES COMPOSED OF 2'-DEOXY-7-DEAZAXANTHOSINE AND 2'-DEOXY-7-DEAZAGUANOSINE AND RELATED ANALOGS | GILEAD SCIENCES, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1992014842-A1 | APTAMERS SPECIFIC FOR THROMBIN AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| WO-1992005186-A1 | MODIFIED INTERNUCLEOSIDE LINKAGES | GILEAD SCIENCES (US) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | DDX41, DDX5, DDX6 | YTHDC1 302/4885YTHDF2 327/4885PDPK1 4470/4885 |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CD63, FLT4, NCL | YTHDC1 2138/4885YTHDF2 1769/4885PDPK1 3523/4885 |
| US-20260041702-A1 | AGENTS THAT INHIBIT CCN LIGAND-INDUCED SIGNALLING FOR TREATING DISEASE | PKD2, CCNK, PKD1 | YTHDC1 4133/4885YTHDF2 3421/4885PDPK1 159/4885 |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | PDCD1, TIA1, NSUN2 | YTHDC1 463/4885YTHDF2 691/4885PDPK1 1914/4885 |
| US-12638452-B2 | Nanopore assemblies and uses thereof | FAM83A, SCNN1G, SCN3A | YTHDC1 2793/4885YTHDF2 2486/4885PDPK1 2820/4885 |
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | CD47, CD2BP2, CD40LG | YTHDC1 797/4885YTHDF2 360/4885PDPK1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.